About
Pharvaris Bv (NASDAQ:PHVS) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 20 2026
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
Apr 2 2026
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Mar 11 2026
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
Mar 2 2026
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
Feb 10 2026
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
Financials
Revenue
$0
Market Cap
$1.86 B
EPS
-3.44
Google Übersetzer